View Older Stories
-
Glaukos Corporation (GKOS) PT Raised to $160 at Stifel
-
UBS Reiterates Buy Rating on Glaukos Corporation (GKOS)
-
Piper Sandler on Glaukos Corporation (GKOS): 'Strong Q4 Print Overshadowed Some By iDose Buy-Side Bogey'
-
Glaukos reports preliminary Q4 2025 sales of $143 million, up 36%
-
Glaukos Corporation (GKOS) PT Raised to $145 at Stephens
-
BTIG Reiterates Buy Rating on Glaukos Corporation (GKOS)
-
Piper Sandler on Glaukos Corporation (GKOS): 'Our 2026 Top Idea'
-
Glaukos Corporation (GKOS) Reiterated at Buy by Stifel
-
Glaukos Corporation (GKOS) PT Raised to $125 at Needham
-
Stifel Reiterates Buy Rating on Glaukos Corporation (GKOS)
-
Stifel Reiterates Buy Rating on Glaukos Corporation (GKOS)
-
UBS Reiterates Buy Rating on Glaukos Corporation (GKOS)
-
Stifel Reiterates Buy Rating on Glaukos Corporation (GKOS)
-
Truist on Glaukos Corporation (GKOS): 'Strong 3Q Beat Led by iDos'
-
Glaukos Corporation (GKOS) PT Raised to $117 at Needham
-
Glaukos Corporation (GKOS) PT Raised to $116 at BTIG
-
Glaukos Corporation (GKOS) Tops Q3 EPS by 10c, provides guidance
-
Glaukos Corporation (GKOS) Can Grow Revenue 30%+ for Years With Epioxa- Stifel
-
Glaukos (GKOS) reiterated at Buy as Epioxa checks come back bullish: Stifel
-
Goldman Sachs Starts Glaukos Corporation (GKOS) at Buy
-
Piper Sandler Reiterates Overweight Rating on Glaukos Corporation (GKOS)
-
Glaukos breaks ground on $80 million Alabama manufacturing facility
-
Stifel Reiterates Buy Rating on Glaukos Corporation (GKOS) Following iDose Survey Results
-
Glaukos Corporation (GKOS) PT Lowered to $130 at Mizuho
-
Glaukos Corporation (GKOS) Tops Q2 EPS by 2c, provides guidance
-
Stifel on Glaukos (GKOS): 'we walked away with increased conviction that iDose reimbursement progress is a “when” and not an “if”'
-
Glaukos Corporation (GKOS) Announces EU MDR Certification for iStent infinite and Other Leading MIGS Therapies
-
Piper Sandler Highlights Top Medtech Picks and Catalyst-Rich Names
-
Stifel Reiterates Buy Rating on Glaukos Corporation (GKOS)
-
Glaukos Corporation (GKOS) PT Lowered to $115 at Stephens
-
Glaukos Corporation (GKOS) PT Lowered to $115 at Needham
-
Glaukos Corporation (GKOS) PT Lowered to $100 at JPMorgan
-
Glaukos Corporation (GKOS) Tops Q1 EPS by 13c ; Offers Guidance
-
Glaukos Corporation (GKOS) PT Lowered to $140 at Stifel
-
Piper Sandler on Glaukos Corporation (GKOS): 'iDose To Drive Upside In Coming Yrs'; PT Lowered
-
These 11 stocks are Mizuho's Aging Intelligence (AI) top picks
-
Stifel Reiterates Buy Rating on Glaukos Corporation (GKOS)
-
Glaukos Corporation (GKOS) Announces FDA Acceptance of NDA Submission for Epioxa
-
Truist Reiterates Buy Rating on Glaukos Corporation (GKOS): 'Buy Dips'
-
Glaukos Corporation (GKOS) PT Raised to $176 at Needham
-
Glaukos Corporation (GKOS) PT Lowered to $155 at BTIG
-
Glaukos Corporation (GKOS) Misses Q4 EPS by 2c, Beats on Revenue; Offers FY25 Revenue Guidance
-
Truist on Glaukos Corporation (GKOS): 'Survey Supports Bull Case (Or Better) Upside Scenarios'
-
Piper Sandler's KOL Calls iDose a 'Game-Changer'; Glaukos Corporation (GKOS) PT Raised to $180
-
MedTech sector outlook for 2025: Truist Securities
-
Glaukos Corporation (GKOS) Announces Positive Clinical Updates for its iDose Sustained-Release Procedural Pharmaceutical Platform
-
Glaukos Corporation (GKOS) PT Raised to $175 at Stifel
-
Glaukos Corporation (GKOS) Submits New Drug Application to U.S. FDA for Epioxa
-
Medical Technology and Devices: Piper Sandler Shares 'Quick Thoughts on HC Conference in Jan'
-
Glaukos Corporation (GKOS) PT Raised to $140 at Mizuho

